AIM ImmunoTech Shares Positive Results from Study
The data reveals strong evidence supporting the immune-stimulatory effects associated with TLR-3 activation through Ampligen.
Further commentary has been published, exploring the potential of Ampligen alongside two other drugs.
AIM ImmunoTech Inc. (NYSE American: AIM) announced today the publication of a data analysis from a long-term Early Access Program that studied the company’s drug Ampligen for treating advanced pancreatic ductal adenocarcinoma. This manuscript, titled Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses, has been featured in the journal Clinical Cancer Research, which is recognized as one of the leading publications in oncology.
Understanding Ampligen's Role and Effects
Ampligen is a dsRNA product candidate that operates through the TLR-3 receptor found on various immune cells, epithelial cells, and tumors. Researchers discovered that treatment with Ampligen in pancreatic cancer patients boosts peripheral immune activity at both the transcriptomic and proteomic levels, particularly affecting type 1 conventional dendritic cells (cDC1s) and T cells. The increase in peripheral abundance was linked to better clinical outcomes, demonstrating a significant overexpression of genes associated with the activation of dendritic and T cells.
“We are thankful to the Erasmus team for their ongoing contributions to the development of Ampligen,” stated AIM Chief Executive Officer Thomas K. Equels. “There is a substantial and growing unmet need for safe and effective treatments for pancreatic cancer. This data continues to shed light on Ampligen’s potential to enhance both progression-free and overall survival.”
Expert Perspectives on Ampligen
Prof. Casper H.J. van Eijck, MD, PhD, a Pancreato-biliary Surgeon, remarked, “We remain optimistic about this data indicating that Ampligen infusions can modulate PD-L1 and PD-L2 expression within the tumor microenvironment while increasing Ki67+CD4+ and Ki67+CD8+ T-cells. We are making headway in the ongoing DURIPANC trial, which is exploring the combination effects of Ampligen with other therapies.”
Recent Insights and Upcoming Trials
Alongside the published manuscript, additional commentary has been released discussing the potential of Ampligen and two other drugs. Key points include:
- Ampligen has been safely administered through a systemic route.
- Notable increases in cDC1 numbers and cytokines that regulate T-cell activation and migration were observed.
- Researchers noted a significant enrichment of B-cell numbers in the peripheral blood, which correlates with long-term survival.
AIM is currently assessing Ampligen for metastatic pancreatic ductal adenocarcinoma in the Phase 1b/2 DURIPANC clinical study and for locally advanced pancreatic adenocarcinoma in the Phase 2 AMP-270 clinical study.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharmaceutical company dedicated to researching and developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19. The company’s leading product is Ampligen, a first-in-class investigational drug that acts as a dsRNA TLR3 agonist with broad-spectrum activity in clinical trials addressing significant global health challenges.
For more information, please visit aimimmuno.com or connect with the Company on social media.
Frequently Asked Questions
What is Ampligen used for?
Ampligen is being investigated as a treatment for advanced pancreatic cancer and other conditions due to its immune-stimulatory properties.
What were the findings of the study?
The study demonstrated that Ampligen enhanced immune activity and improved clinical outcomes in patients with pancreatic cancer.
Who conducted the research on Ampligen?
The research was conducted by the Erasmus University Medical Center.
What is the significance of TLR-3 activation?
Activation of TLR-3 enhances immune responses, which may lead to improved outcomes in cancer treatment.
How can I learn more about AIM ImmunoTech?
To find more information about AIM ImmunoTech, you can visit their website.
